---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000055"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:49:58.409233+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GRI Bio receives Nasdaq delisting determination; plans to appeal by May 28, 2024

## Summary
- Received Nasdaq Staff determination letter on May 21, 2024, for non-compliance with stockholders' equity rule (Rule 5550(b)) after initial 180-day cure period ended May 20, 2024.
- Despite reporting >$2.5M equity as of March 31, 2024, Nasdaq considered historical burn rate and concluded non-compliance.
- Company intends to request a hearing before a Nasdaq Hearings Panel by May 28, 2024, which will automatically stay suspension/delisting pending outcome.
- Panel may grant up to 180-day extension, but no guarantee of regaining compliance or continued listing.

## SEC filing metadata
- accession: 0001824293-24-000055
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000055/0001824293-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000055/val-20240521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000055
- JSON: https://secwatch.observer/filing/0001824293-24-000055.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.